Why PROCEPT BioRobotics Corporation’s (PRCT) Stock Is Down 5.14%
As of Tuesday, September 08, PROCEPT BioRobotics Corporation’s PRCT share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: PROCEPT BioRobotics Corporation (PRCT)
PROCEPT BioRobotics Corporation PRCT
$20.07
-0.67
-3.23%
September 10, 2026 4:00:00 PM
EST
Volume: 975,535
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Commentary & Analysis
Why PROCEPT BioRobotics Corporation’s (PRCT) Stock Is Up 5.85%
As of Friday, September 04, PROCEPT BioRobotics Corporation’s PRCT share price has surged by 5.85%, which has investors questioning if this is right time to sell.Jenna Brashear
Why PROCEPT BioRobotics Corporation’s (PRCT) Stock Is Up 5.69%
As of Friday, August 21, PROCEPT BioRobotics Corporation’s PRCT share price has surged by 5.69%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why PROCEPT BioRobotics Corporation’s (PRCT) Stock Is Down 5.37%
As of Wednesday, August 12, PROCEPT BioRobotics Corporation’s PRCT share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Is PROCEPT BioRobotics Corporation (PRCT) Overvalued?
We dive into why PROCEPT BioRobotics Corporation (PRCT) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | PRCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,149.5 | $397.9 | 47% |
|
| Shares Out (Mil) | 57.1 | 40.8 | 50% |
|
| Institutional Ownership | 97.5% | 83.6% | 74% |
|
| Float (Mil) | 55.8 | 35.5 | 49% |
|
| Beta | 0.90 | 0.88 | 54% |
|
| Avg Daily Volume (000s) | 1,105 | 323 | 73% |
|
| Price Change (52-week) |
(49.2%) | 63.7% | 16% |
|
| Growth | PRCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 109.1% | 11.8% | 99% |
|
| Net Income (5yr) | (12.5%) | (5.8%) | 27% |
|
| EPS (5yr) | 34.7% | 10.4% | 85 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.5%) | (15.5%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 11 | 11 | |
| Current EPS | ($0.388) | ($1.680) | ($1.153) | |
| Month Ago EPS | ($0.388) | ($1.680) | ($1.153) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 2 | 1 | 0 | |
| Three Months Ago EPS | ($0.336) | ($1.515) | ($0.866) | |
| Year/Year Chg | (17.6%) | (2.4%) | (51.4%) | |
| Financials | PRCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $337 | $119 | 37% |
|
| Net Income (TTM) (Mil) | ($110) | ($9) | 10% |
|
| EPS (TTM) | ($1.948) | ($0.400) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($74) | ($3) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($75) | $1 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $75 | $23 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,153 | $371 | 42% |
|
| Valuation | PRCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.38 | 2.73 | 69% |
|
| P/E | na | 25.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | PRCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.4% | 58.3% | 76% |
|
| Net Margin | (32.5%) | (6.9%) | 14% |
|
| ROA | (22.1%) | (12.7%) | 20% |
|
| ROE | (30.2%) | (12.3%) | 20% |
|
| Liabilities to Assets | 29.1% | 46.0% | 21% |
|
| F-Score | 3 | 4 | 18% |
|
PROCEPT BioRobotics Corporation did not pass any screens on 9/10/2026.
